Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
Arvinas, a clinical-stage biotechnology company, is set to present updated Phase 1/2 trial data for its investigational drug, bavdegalutamide (ARV-110), at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. The event, taking place in Madrid, Spain from October 20-24, will provide an opportunity for Arvinas to showcase the potential of bavdegalutamide as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC).
Bavdegalutamide is an orally bioavailable PROTAC® androgen receptor (AR) degrader, designed to selectively target and degrade the androgen receptor. This mechanism of action makes it a promising candidate for addressing the challenges posed by AR mutation or overexpression, which can lead to resistance to currently available AR-targeted therapies.
The Phase 1/2 trial data will be presented by Dr. Daniel Petrylak during a poster session on October 22. This presentation will shed light on the progress and potential of bavdegalutamide in treating mCRPC, offering hope to patients and healthcare professionals alike.
Arvinas is dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. The company utilizes its proprietary PROTAC® Discovery Engine platform to develop therapies that degrade disease-causing proteins. By harnessing the body’s natural protein disposal system, Arvinas aims to selectively and efficiently remove disease-causing proteins, ultimately leading to improved patient outcomes.
In addition to bavdegalutamide, Arvinas has two other investigational clinical-stage programs focused on treating metastatic prostate cancer: ARV-766 and vepdegestrant (ARV-471). These programs, along with the robust preclinical pipeline of PROTAC protein degraders, demonstrate Arvinas’ commitment to addressing unmet medical needs and advancing the field of targeted protein degradation.
The upcoming conference and webcast call on October 22 will provide an opportunity for investors and stakeholders to gain further insights into the poster presentation and Arvinas’ progress. The live audio webcast will be available on the company’s website, and a replay will be archived for those unable to attend the event.
Arvinas’ dedication to scientific innovation and its commitment to developing therapies that have the potential to transform patients’ lives make it a key player in the biotechnology industry. With its focus on targeted protein degradation, Arvinas is paving the way for novel treatment approaches that could revolutionize the field of oncology and beyond.
For more information about Arvinas and its pipeline of therapies, visit their official website.